Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical tr… Read more
Vivoryon Therapeutics N.V. (0R3M) - Net Assets
Latest net assets as of June 2025: €3.18 Million EUR
Based on the latest financial reports, Vivoryon Therapeutics N.V. (0R3M) has net assets worth €3.18 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.42 Million) and total liabilities (€3.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.18 Million |
| % of Total Assets | 49.56% |
| Annual Growth Rate | -3.1% |
| 5-Year Change | -69.95% |
| 10-Year Change | 48743.98% |
| Growth Volatility | 924285.07 |
Vivoryon Therapeutics N.V. - Net Assets Trend (2010–2024)
This chart illustrates how Vivoryon Therapeutics N.V.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vivoryon Therapeutics N.V. (2010–2024)
The table below shows the annual net assets of Vivoryon Therapeutics N.V. from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €7.88 Million | -70.02% |
| 2023-12-31 | €26.28 Million | -0.85% |
| 2022-12-31 | €26.51 Million | +60.09% |
| 2021-12-31 | €16.56 Million | -36.86% |
| 2020-12-31 | €26.22 Million | -38.54% |
| 2019-12-31 | €42.66 Million | +3468599.19% |
| 2018-12-31 | €1.23K | -86.22% |
| 2017-12-31 | €8.92K | -45.51% |
| 2016-12-31 | €16.38K | +1.51% |
| 2015-12-31 | €16.13K | +1.01% |
| 2014-12-31 | €15.97K | +100.38% |
| 2013-12-31 | €-4.22 Million | -178.73% |
| 2012-12-31 | €5.37 Million | -64.10% |
| 2011-12-31 | €14.95 Million | +22.11% |
| 2010-12-31 | €12.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vivoryon Therapeutics N.V.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13257800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €261.00K | 3.31% |
| Other Comprehensive Income | €-268.00K | -3.40% |
| Other Components | €177.25 Million | 2249.42% |
| Total Equity | €7.88 Million | 100.00% |
Vivoryon Therapeutics N.V. Competitors by Market Cap
The table below lists competitors of Vivoryon Therapeutics N.V. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MBT Bancshares Inc
PINK:MBKL
|
$20.35 Million |
|
JHM Consolidation Bhd
KLSE:0127
|
$20.36 Million |
|
Ultimate Holdings Group Inc.
OTCGREY:UHGI
|
$20.36 Million |
|
088340
KQ:088340
|
$20.38 Million |
|
TOUAX INH. EO 8
F:TOX
|
$20.35 Million |
|
TeraGo Inc
PINK:TRAGF
|
$20.34 Million |
|
iMBC Co.Ltd
KQ:052220
|
$20.34 Million |
|
iCRAFT Co. Ltd
KQ:052460
|
$20.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vivoryon Therapeutics N.V.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,282,000 to 7,880,000, a change of -18,402,000 (-70.0%).
- Net loss of 20,568,000 reduced equity.
- Other comprehensive income decreased equity by 13,611,000.
- Other factors increased equity by 15,777,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-20.57 Million | -261.02% |
| Other Comprehensive Income | €-13.61 Million | -172.73% |
| Other Changes | €15.78 Million | +200.22% |
| Total Change | €- | -70.02% |
Book Value vs Market Value Analysis
This analysis compares Vivoryon Therapeutics N.V.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.47x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.66x to 4.47x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | €2.04 | €1.35 | x |
| 2012-12-31 | €0.73 | €1.35 | x |
| 2013-12-31 | €-0.58 | €1.35 | x |
| 2014-12-31 | €0.00 | €1.35 | x |
| 2015-12-31 | €0.00 | €1.35 | x |
| 2016-12-31 | €0.00 | €1.35 | x |
| 2017-12-31 | €0.00 | €1.35 | x |
| 2018-12-31 | €0.00 | €1.35 | x |
| 2019-12-31 | €3.40 | €1.35 | x |
| 2020-12-31 | €1.31 | €1.35 | x |
| 2021-12-31 | €0.83 | €1.35 | x |
| 2022-12-31 | €1.20 | €1.35 | x |
| 2023-12-31 | €1.04 | €1.35 | x |
| 2024-12-31 | €0.30 | €1.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vivoryon Therapeutics N.V. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -261.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.43x
- Recent ROE (-261.02%) is above the historical average (-68572.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -109.11% | -77652.38% | 0.00x | 1.28x | €-17.80 Million |
| 2012 | -348.93% | -312000.00% | 0.00x | 1.86x | €-19.26 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | €-9.51 Million |
| 2014 | -71611.05% | 0.00% | 0.00x | 1.34x | €-11.44 Million |
| 2015 | -83710.41% | 0.00% | 0.00x | 1.36x | €-13.51 Million |
| 2016 | -84825.35% | 0.00% | 0.00x | 1.37x | €-13.89 Million |
| 2017 | -89756.81% | 0.00% | 0.00x | 1.21x | €-8.01 Million |
| 2018 | -629024.39% | 0.00% | 0.00x | 3.29x | €-7.74 Million |
| 2019 | -18.34% | 0.00% | 0.00x | 1.07x | €-12.09 Million |
| 2020 | -62.96% | 0.00% | 0.00x | 1.13x | €-19.13 Million |
| 2021 | -76.43% | -117.57% | 0.44x | 1.48x | €-14.31 Million |
| 2022 | -106.23% | 0.00% | 0.00x | 1.18x | €-30.81 Million |
| 2023 | -107.84% | 0.00% | -0.12x | 1.17x | €-30.97 Million |
| 2024 | -261.02% | 0.00% | 0.00x | 1.43x | €-21.36 Million |
Industry Comparison
This section compares Vivoryon Therapeutics N.V.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vivoryon Therapeutics N.V. (0R3M) | €3.18 Million | -109.11% | 1.02x | $20.35 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |